Core Viewpoint - Osisko Development Corp. has announced a private placement offering to raise approximately US$120 million to fund the Cariboo Gold Project and general corporate purposes [1][5]. Group 1: Offering Details - The company will issue 58,560,000 units at a price of US$2.05 per unit, resulting in gross proceeds of US$120,048,000 [1]. - Each unit consists of one common share and one-half of a common share purchase warrant, with the warrants exercisable at US$2.56 for 24 months [2]. - The underwriters have an option to purchase an additional 2,440,000 units, bringing the total offering size to a maximum of US$125 million [3]. Group 2: Strategic Investor Participation - Concurrently, the company plans a non-brokered private placement of 36,600,000 units to a strategic investor for gross proceeds of US$75,030,000 [4]. - An investor rights and voting support agreement will be established with the strategic investor, allowing them to identify a director for the company board [4]. Group 3: Use of Proceeds - The net proceeds from both the offering and the non-brokered private placement will be used to fund the equity portion of the Cariboo Gold Project and for general corporate purposes [5]. - The company anticipates that these funds, along with a US$450 million project loan credit facility, will be sufficient to construct the Cariboo Gold Project [5]. Group 4: Timeline and Regulatory Approvals - The offering is expected to close around August 15, 2025, pending necessary regulatory approvals from the TSX Venture Exchange and the New York Stock Exchange [6].

Core Viewpoint - XORTX Therapeutics Inc. is conducting a non-brokered private placement to raise up to USD $114.5 million through the issuance of common share units at a price of USD $0.73 per unit, aimed at funding its gout and kidney disease treatment programs [1][3]. Group 1: Offering Details - The private placement will consist of up to 156,849 common share units, each unit comprising one common share and one common share purchase warrant [1]. - Each warrant allows the holder to purchase an additional common share at USD $1.20 for 60 months, with an acceleration clause if the share price exceeds USD $2.00 for 10 consecutive trading days [1]. - The closing date for the offering is expected around August 5, 2025, subject to necessary approvals [3]. Group 2: Use of Proceeds - Proceeds from the offering will be allocated to gout programs, general corporate purposes, and working capital [3]. Group 3: Company Overview - XORTX Therapeutics is focused on developing innovative therapies for gout and progressive kidney disease, with three advanced clinical products: XRx-026 for gout, XRx-008 for ADPKD, and XRx-101 for acute kidney injury [4]. - The company is also developing XRx-225, a pre-clinical program for Type 2 diabetic nephropathy, targeting purine metabolism and xanthine oxidase to reduce uric acid production [4].

Core Viewpoint - MetalQuest Mining Inc. has successfully completed a non-brokered private placement, raising $517,296 through the issuance of 7,389,943 units, subject to final approval from the TSX Venture Exchange [1][2]. Financing Details - Each unit consists of one common share and one non-transferable share purchase warrant, allowing the holder to purchase an additional common share at $0.10 for three years [2]. - The proceeds will be allocated for exploration, development, and general working capital [2]. Insider Participation - New Age Metals Inc. will increase its ownership in MQM from approximately 6.44% to 19.05% post-conversion, becoming a new insider [2][4]. - Existing insiders and control persons purchased a total of 4,868,000 units, qualifying as a related party transaction [4]. Regulatory Compliance - All securities from the private placement are subject to a four-month hold period under Canadian Securities Laws [3]. - The company is relying on exemptions from formal valuation and minority shareholder approval requirements due to the nature of the transaction [4]. Shareholder Control - Prior to the offering, Mr. Harry Barr controlled 8,616,438 common shares, which could increase to approximately 33.28% post-offering if stock options are exercised [5]. - After the offering, Barr's control could rise to approximately 47.27% of the company's outstanding shares, while New Age Metals could control about 19.05% [8][9]. Company Overview - MetalQuest Mining owns 100% of the Lac Otelnuk Iron Ore Project in Quebec, which is one of the largest iron ore projects in North America [12]. - The company has invested approximately $150 million in the project and is working with the Naskapi First Nation on exploration and pre-development [12]. - A comprehensive gap analysis of the historic feasibility study is being conducted to align with current market dynamics and regulatory standards [12].

Lake Victoria Gold Announces Non-Brokered LIFE Private Placement of Units and Concurrent Private Placement of Common Shares July 31, 2025 6:00 AM EDT | Source: Lake Victoria Gold Ltd. Vancouver, British Columbia--(Newsfile Corp. - July 31, 2025) - Lake Victoria Gold Ltd. (TSXV: LVG) ("LVG" or the "Company") is pleased to announce that it intends to complete a non-brokered private placement (the "LIFE Private Placement") consisting of the issuance of units of the Company (the "Units") at a price of $0.175 pe ...

Core Viewpoint - Revive Therapeutics Ltd. is proposing a private placement offering of up to 30,952,381 units at a price of $0.021 per unit, aiming for gross proceeds of up to $650,000, while also settling a note payable of $67,400 through the issuance of additional units at the same price [1][3]. Group 1: Private Placement Details - The private placement will consist of units, each comprising one common share and one common share purchase warrant, with warrants allowing the purchase of one common share at an exercise price of $0.05 for 36 months post-closing [2]. - The gross proceeds from the offering will be allocated for working capital and settling certain trade payables, with the potential for the placement to close in multiple tranches [3]. Group 2: Closing Conditions and Securities - The closing of the private placement and debt settlement is subject to customary closing conditions, with the company intending to close as soon as practicable [4]. - All securities issued will be subject to a hold period of four months and one day from the issuance date [4]. Group 3: Company Overview - Revive Therapeutics is focused on developing innovative therapeutics for critical medical needs, prioritizing its drug development pipeline to leverage FDA regulatory incentives for rapid advancement and market entry [5]. - Current efforts are concentrated on the potential of Bucillamine for infectious diseases and medical countermeasures, alongside advancing Psilocybin and molecular hydrogen therapeutic programs [5].

Core Points - Giga Metals Corp. has successfully closed the first tranche of its non-brokered private placement financing, which was announced on July 17, 2025 [1][6] - The first tranche raised gross proceeds of $310,414 from the sale of 3,449,039 flow-through units at $0.09 each and $156,000 from 1,950,000 hard dollar units at $0.08 each [2] - The proceeds from the flow-through offering will be allocated to advance the Turnagain project and other potential Canadian properties, with a commitment to incur eligible Canadian exploration expenses [4] Financial Details - Each flow-through unit consists of one common share and one purchase warrant, while each hard dollar unit consists of one common share and one purchase warrant [3] - The warrants are exercisable at $0.11 for three years, expiring on July 30, 2028 [3] - Finder's fees for the offering amounted to $24,738 in cash and 281,488 finder's warrants, which are also exercisable into common shares at $0.08 each for three years [5] Future Plans - A second tranche of the private placement is expected to close around August 13, 2025, subject to regulatory approvals [6] - Giga Metals Corporation's core asset is the Turnagain Project, which contains significant undeveloped sulphide nickel and cobalt resources [8]

ETH TreasuryCo - Fundamental Global 启动了一个 2 亿美元的 ETH TreasuryCo 私募项目 [1] 行业动态 - 又一个 9 位数（百万美元级别）的 ETH TreasuryCo 成立 [1]

Group 1 - TinOne Resources Inc. has adjusted the pricing of its non-brokered private placement, now offering up to 4,000,000 units at a revised price of $0.05 per unit, aiming for gross proceeds of up to $200,000 [1][2] - Each unit consists of one common share and one whole common share purchase warrant, with the warrant allowing the purchase of one common share at an exercise price of C$0.06 for five years [1] - The proceeds from the offering will be used to maintain the company and its tenements in good standing, as well as for general working capital purposes [3] Group 2 - The company may pay finder's fees of up to 6% in cash and up to 6% in finder's warrants to eligible finders in connection with the offering [2] - The closing of the offering is subject to necessary approvals, including that of the Board of Directors and the TSX Venture Exchange [2] - All securities issued will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with Canadian securities legislation [2] Group 3 - TinOne is a TSX Venture Exchange listed Canadian public company with a portfolio of tin projects in Tasmania, Australia, focusing on advancing its projects while evaluating additional opportunities [4]

Group 1 - Newlox Gold Ventures Corp has successfully closed a private placement that was oversubscribed by $171,320, raising a total of $2,171,320 through the issuance of 31,018,857 units at a price of $0.07 per unit [1][2] - Each unit consists of one common share and one common share purchase warrant, with the warrant allowing the holder to acquire a share at $0.12 until July 28, 2028 [2][4] - The proceeds from the offering will be used for continued milling operations in Costa Rica and for general working capital [6] Group 2 - The company paid a finders' fee of $27,241 and issued 778,314 non-transferable broker warrants as part of the offering [3] - Related party transactions occurred as directors and/or officers of the company subscribed for 9,500,000 units, totaling $665,000, which did not exceed 25% of the company's market capitalization [5] - All securities issued are subject to a statutory hold period of four months and one day [7] Group 3 - Newlox Gold Ventures Corp is focused on recovering gold and silver from artisanal and small-scale mining operations in Latin America, utilizing technology to recover precious metals while also remediating historical mine waste [8]

Core Viewpoint - Germanium Mining Corp. has successfully closed a non-brokered private placement, raising gross proceeds of $175,000 through the issuance of 1,750,000 units at a price of $0.10 per unit, which includes common shares and warrants [1] Group 1: Private Placement Details - Each unit in the private placement consists of one common share and one transferable common share purchase warrant, with each warrant allowing the purchase of an additional share at $0.12 for 24 months [1] - The company has settled $424,753 in accounts payable through the issuance of 4,247,533 common shares at $0.10 per share [1] Group 2: Regulatory Compliance - The company relied on an exception from the requirement to obtain shareholder approval for issuing more than 100% of its issued share capital on a fully diluted basis due to financial hardship and other conditions [2] - Independent Directors of the company determined that the offering is in the best interests of the company and that obtaining shareholder approval was not feasible [2] Group 3: Use of Proceeds - The net proceeds from the private placement will be allocated towards exploration activities and general corporate purposes, including arm's length payables [3] - All securities issued will be subject to a statutory hold period of four months and one day as required under applicable securities legislation [3]